The FDA has accepted the resubmitted BLA for linvoseltamab for patients with relapsed/refractory multiple myeloma.

DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...

Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical ...

Chugai Pharmaceutical has launched Lunsumio (mosunetuzumab) in Japan for patients with relapsed or refractory follicular ...

Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...

DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...

Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete remission ...

As sextortion grows, so does the prevalence of individuals or companies that charge a fee to retrieve explicit photos, and ...

The data from the Phase 1/1b clinical trial of soquelitinib in patients with T cell lymphoma continues to demonstrate strong indications of anti-tumor activity in a significant number of patients,” ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

Combining BET inhibitors and PARP inhibitors might help patients resistant to chemotherapy, the study suggests.

Hailey Bieber may finally be putting her foot down, as the model is reportedly exploring her legal options after a new TikTok ...